Your session is about to expire
← Back to Search
Safety Lead-In for Acute Myeloid Leukemia
Study Summary
This trial aims to determine if giving oral decitabine-cedazuridine with thioguanine is effective and safe for patients with acute myeloid leukemia that has come back or not
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are potential candidates able to apply for participation in this ongoing trial?
"As detailed on clinicaltrials.gov, this research endeavor is actively seeking suitable participants. The trial was published on January 30th, 2024 and last revised on April 2nd, 2024."
What is the current number of participants being enlisted for this clinical trial?
"Indeed, the details on clinicaltrials.gov highlight that recruitment is ongoing for this investigation. The trial was first listed on January 30, 2024 and most recently revised on April 2, 2024. A total of 48 individuals are sought from a single site."
What is the safety profile of the Safety Lead-In method for patients?
"Given that Safety Lead-In is a Phase 2 trial without efficacy data but with some safety information, it has been rated as a 2 on our scale of assessment."
Share this study with friends
Copy Link
Messenger